tirzepatide approval obesity FDA Approves Tirzepatide, A Potential Blockbuster Drug for Type 2 Diabetes tirzepatide come in pill form
Description
The primary goal remains consistent subcutaneous delivery in areas with adequate tissue depth, regardless of the specific location within the approved anatomical regions
In clinical trials (SURMOUNT programme), tirzepatide produced average weight loss of 1522% of body weight significantly greater than semaglutide (Wegovy), making it the most effective weight loss medication currently available
Should a person suddenly start losing a lot of weight, their body will consider it a kind of stress
Most common side effects (according to the company's safety information): Nausea, vomiting, diarrhea, constipation, bloating or gas, and decreased appetite or early satiety
Regular communication with your medical provider about your experience usually improves outcomes
